With a market capitalization (market cap) of $1.01B — a measure of how much the company is worth — Candel Therapeutics, Inc. is the 2583rd most valuable company in Healthcare as of August 27, 2026. Shares trade at $13.83, up +4.10% on the day.
of 2,596
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Visit websiteAs of August 27, 2026, Candel Therapeutics, Inc. (CADL) is worth $1.02B — this is its market capitalization, the total value of all its outstanding shares.
Candel Therapeutics, Inc.’s market cap is $1.02B, which ranks it #2583 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Candel Therapeutics, Inc. (CADL) shares trade at $13.87, up 4.41% on the day, as of August 27, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025